{"access":{"can_view":true,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":false,"can_get_doi":false,"can_share":true,"can_move":true,"can_move_outside":true,"can_transfer":true,"can_download":true,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"authors":[{"name":"Ghalia Missous","affiliation":"Sidra Medicine","affiliation_url":null,"username":"ghalia-missous","link":null,"image":{"source":"/img/avatars/002.png","placeholder":"/img/avatars/002.png","webp_source":""},"note":"","is_verified_user":true},{"name":"Nicholas Van Panhuys","affiliation":"Sidra Medicine","affiliation_url":null,"username":"n4vle152z1z4ule1","link":null,"image":{"source":"/img/avatars/016.png","placeholder":"/img/avatars/016.png","webp_source":""},"note":"","is_verified_user":false}],"before_start":"{\"blocks\":[{\"key\":\"fcu3j\",\"text\":\"\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","book_chapter":null,"can_accept_authorship":false,"can_be_copied":true,"can_claim_authorship":false,"can_manage_keywords":true,"can_remove_fork":false,"can_sign":false,"child_steps":{},"cited_protocols":[],"collection_items":[],"created_on":1707134083,"creator":{"name":"Ghalia Missous","affiliation":"","affiliation_url":null,"username":"ghalia-missous","link":null,"image":{"source":"/img/avatars/002.png","placeholder":"/img/avatars/002.png","webp_source":""},"badges":[{"id":2,"name":"Author","image":{"source":"/img/badges/bronze.svg","placeholder":"/img/badges/bronze.svg"}}],"affiliations":[]},"cross_cloud_origin":null,"description":"{\"blocks\":[{\"key\":\"egl6g\",\"text\":\"This protocol outlines a systematic review with meta-analyses to comprehensively assess Interleukin-33 (IL-33) levels in\\nindividuals with Type 2 Diabetes (T2D) and obesity compared to healthy controls. Existing literature suggests a potential association between IL-33 and metabolic conditions, but conflicting findings necessitate a systematic evaluation. Expected results will contribute insights into the role of IL-33 in T2D and obesity, guiding future research and clinical implications.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","disclaimer":"","document":"","documents":[{"id":440939,"guid":"","type_id":0,"filename":"","key":"","color":"","height":0,"width":0,"is_document":null,"original_file_id":null,"thumb_url":"https://www.protocols.io/img/extensions/pdf.png","size":177267,"is_private":0,"is_new":0,"ofn":"Protocol for a Systematic Review with MetaA.pdf","url":"https://content.protocols.io/files/pqvmcb7dx.pdf","bucket_name":null,"s3_webp_url":"","file_id":440939}],"doi":"dx.doi.org/10.17504/protocols.io.4r3l22k63l1y/v1","doi_status":1,"ethics_statement":null,"fork_id":null,"fork_info":null,"forks":[],"funders":[{"funder_name":"the Qatar National Research Fund ","grant_id":"NPRP11S-0122-180359"}],"groups":[],"guid":"8A6D061F4865440994A4EFC1E96B0A0F","guidelines":"{\"blocks\":[{\"key\":\"app7r\",\"text\":\"This systematic review and meta-analyses adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","has_references":true,"has_step_reagents":false,"has_versions":false,"id":94691,"image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"image_attribution":"","in_trash":false,"is_bookmarked":false,"is_contact_suspended":false,"is_content_confidential":false,"is_content_warning":false,"is_doi_reserved":true,"is_in_pending_publishing":false,"is_in_transfer":false,"is_owner":true,"is_research":true,"is_retracted":false,"is_shared_directly":false,"is_subprotocol":null,"is_unlisted":false,"item_id":1214194,"journal":null,"journals":[],"keywords":"","last_modified":1707144665,"link":"","location":null,"manuscript_citation":"","materials":[],"materials_text":"","ownership_history":null,"parent_collections":[],"parent_protocols":[],"peer_reviewed":false,"protocol_references":"{\"blocks\":[{\"key\":\"7lsef\",\"text\":\"\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","public":true,"public_fork_note":"","published_on":1707144665,"references":[],"related_equipments":[],"related_materials":[],"reserved_doi":"10.17504/protocols.io.4r3l22k63l1y/v1","retraction_reason":null,"samples":{},"shared_access_id":265,"show_comparison":false,"sign_info":null,"space_access":{"can_view":false,"can_edit":false,"can_remove":false,"can_add":false,"can_publish":true,"can_get_doi":true,"can_share":false,"can_move":false,"can_move_outside":false,"can_transfer":false,"can_download":false,"limited_run":false,"limited_private_links":false,"limited_blind_links":false,"is_locked":false},"space_id":115862,"state_version_id":99,"stats":{"is_voted":false,"number_of_views":0,"number_of_steps":3,"number_of_bookmarks":0,"number_of_comments":0,"number_of_bookmarked_comments":0,"number_of_steps_comments":0,"number_of_protocol_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"number_of_reagents":0,"number_of_equipments":0,"number_of_collections":0,"number_of_forks":{"private":0,"public":0},"number_of_accessible_forks":0},"status":{"id":1,"info":"We use this protocol and it's working"},"steps":[{"id":1929952,"guid":"6DCDCEB99ABE4F58AF3FD9D7F75F1BEF","previous_id":0,"previous_guid":null,"section":"\u003cp\u003eBackground\u003c/p\u003e","section_color":"#42afff","section_duration":0,"is_substep":false,"step":"{\"blocks\":[{\"key\":\"3nmsv\",\"text\":\"Obesity and Type 2 Diabetes (T2D) pose substantial global\\nhealth challenges, requiring effective interventions [1,2]. While the Interleukin-1 cytokine family,\\nspecifically IL-1α and IL-1β, has been extensively studied for its role in\\nassociated metabolic dysfunction [3], IL-33, also part of this family, emerges as\\na promising therapeutic agent influencing inflammation-metabolism interplay.\\nAnimal models elucidate IL-33's role in regulating brown adipose tissue,\\ncontributing to thermogenesis and overall metabolic health[4]. Human studies reveal lower serum IL-33\\nlevels in lean individuals, suggesting potential implications for obesity and\\nT2D [5].\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"9krmm\",\"text\":\"Despite these insights, a comprehensive evaluation of serum\\nIL-33 levels in metabolic disorders, particularly obesity and T2D, is notably\\nlacking. This systematic review aims to address the question: What is the\\ndifference in IL-33 serum levels between individuals with obesity and/or T2D\\nand Healthy Controls (HC)? This review will bridge this gap, providing a\\ncritical assessment of existing evidence. By consolidating and appraising the\\ncurrent research landscape on IL-33, this review seeks to enhance our understanding\\nof the underlying mechanisms contributing to these prevalent conditions,\\nultimately guiding future research and therapeutic strategies.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","data":null,"protocol_id":94691,"case_id":0,"critical_ids":"","duration":0,"original_id":0,"number":"1","cases":[],"critical":null},{"id":1930177,"guid":"27EE368DBD7C4B168C5676175DB33BF0","previous_id":1929952,"previous_guid":"6DCDCEB99ABE4F58AF3FD9D7F75F1BEF","section":"\u003cp\u003eMethods\u003c/p\u003e","section_color":"#A492FF","section_duration":0,"is_substep":false,"step":"{\"blocks\":[{\"key\":\"ed7t8\",\"text\":\"Search Strategy Protocol:\\n\\nThe search will adhere to the Preferred Reporting Items for Systematic Reviews\\nand Meta-Analyses (PRISMA) guidelines. Scopus, PubMed, and Web of Science will\\nbe selected for their expansive coverage and advanced search capabilities. The\\nsearch strategy will utilize both textwords and Medical Subject Headings (MeSH)\\nterms with Boolean logic operators (AND/OR).\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":25}],\"entityRanges\":[],\"data\":{}},{\"key\":\"11jh1\",\"text\":\"Eligibility Criteria Protocol:\\n\\nTo comply with PRISMA reporting guidelines, a robust theoretical framework will\\nguide the article selection process. The research question centers on\\nelucidating the significance of IL-33 levels in individuals with metabolic\\ndisorders, emphasizing obesity and T2D. Eligible study designs encompass\\nprospective or retrospective cohort studies, case-control studies,\\ncross-sectional studies, and clinical trials assessing IL-33 levels in\\nindividuals with T2D and/or obesity.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":30}],\"entityRanges\":[],\"data\":{}},{\"key\":\"7qhht\",\"text\":\"Study Records:\\n\\nDuring screening, eligibility, and data extraction, studies will be evaluated\\nin duplicate by two independent reviewers. Disagreements will be resolved by\\ninvolving a third reviewer. Data extraction will be organized in a spreadsheet,\\nand for studies with unclear data representation, authors will be contacted or\\nWebPlotDigitalizer will be utilized.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":14}],\"entityRanges\":[],\"data\":{}},{\"key\":\"5oujo\",\"text\":\"Quality Assessment and Risk of Bias:\\n\\nJoanna Briggs Institute (JBI) critical appraisal checklists tailored to\\nspecific study designs will be used for the assessment. Checklist responses\\nwill be categorized, and the overall methodical quality will be classified as\\nhigh, acceptable, or low.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":36}],\"entityRanges\":[],\"data\":{}},{\"key\":\"fot6\",\"text\":\"Statistical Analysis:\\n\\nThe meta package in RStudio will be used for statistical analysis. Mean\\ndifferences (MD) will be chosen as the measure of effect, and pooled MD will be\\ncalculated using random-effects models to accommodate potential heterogeneity.\\nThe heterogeneity of studies will be measured using I-square (I2) and Tau\\nsquare (Tau2). Forest plots will visually present meta-analytic outcomes.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":21}],\"entityRanges\":[],\"data\":{}},{\"key\":\"5c90u\",\"text\":\"Sensitivity Analysis Protocol:\\n\\nSensitivity analyses, including leave-one-out analyses and fixed-effects model\\nassessments, will be conducted to evaluate robustness.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":30}],\"entityRanges\":[],\"data\":{}},{\"key\":\"bu4v5\",\"text\":\"Publication Bias:\\n\\nIf possible, publication bias will be assessed through funnel plots and\\nasymmetry hypothesis tests (Egger's or Begg's).\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":17}],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","data":null,"protocol_id":94691,"case_id":0,"critical_ids":"","duration":0,"original_id":0,"number":"2","cases":[],"critical":null},{"id":1930178,"guid":"9D66BA8A474B4D11940C9D1EFB8CF9B4","previous_id":1930177,"previous_guid":"27EE368DBD7C4B168C5676175DB33BF0","section":"\u003cp\u003eReferences\u003c/p\u003e","section_color":"#94EBFF","section_duration":0,"is_substep":false,"step":"{\"blocks\":[{\"key\":\"bhqcp\",\"text\":\"References:\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[{\"style\":\"bold\",\"offset\":0,\"length\":11}],\"entityRanges\":[],\"data\":{}},{\"key\":\"7oee5\",\"text\":\"\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"r3ni\",\"text\":\"[1]        Tiwari A, Balasundaram P. Public Health Considerations\\n Regarding Obesity. 2023.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"btcpq\",\"text\":\"[2]        Chooi YC, Ding C, Magkos F. The epidemiology of obesity.\\n Metabolism 2019;92:6–10. https://doi.org/10.1016/j.metabol.2018.09.005.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"cs4vd\",\"text\":\"[3]        Banerjee M, Saxena M. Interleukin-1 (IL-1) family of\\n cytokines: Role in Type 2 Diabetes. Clinica Chimica Acta 2012;413:1163–70.\\n https://doi.org/10.1016/j.cca.2012.03.021.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"artmc\",\"text\":\"[4]        Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H,\\n Peldschus K, et al. Brown adipose tissue activity controls triglyceride\\n clearance. Nat Med 2011;17:200–5. https://doi.org/10.1038/nm.2297.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"b0o2f\",\"text\":\"[5]        Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R,\\n Bennakhi A, et al. IL-33 is negatively associated with the BMI and confers a\\n protective lipid/metabolic profile in non-diabetic but not diabetic subjects.\\n BMC Immunol 2014;15. https://doi.org/10.1186/1471-2172-15-19.\",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}},{\"key\":\"c76b1\",\"text\":\"\\n  \",\"type\":\"unstyled\",\"depth\":0,\"inlineStyleRanges\":[],\"entityRanges\":[],\"data\":{}}],\"entityMap\":{}}","data":null,"protocol_id":94691,"case_id":0,"critical_ids":"","duration":0,"original_id":0,"number":"3","cases":[],"critical":null}],"template_id":1,"title":"Circulating Interleukin-33 Levels in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analyses","title_html":"Circulating Interleukin-33 Levels in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analyses","type_id":1,"units":[{"id":1,"type_id":3,"name":"µL","can_manage":0,"read_only":0},{"id":2,"type_id":3,"name":"mL","can_manage":0,"read_only":0},{"id":3,"type_id":3,"name":"L","can_manage":0,"read_only":0},{"id":4,"type_id":3,"name":"µg","can_manage":0,"read_only":0},{"id":5,"type_id":3,"name":"mg","can_manage":0,"read_only":0},{"id":6,"type_id":3,"name":"g","can_manage":0,"read_only":0},{"id":7,"type_id":3,"name":"kg","can_manage":0,"read_only":0},{"id":8,"type_id":3,"name":"ng","can_manage":0,"read_only":0},{"id":9,"type_id":3,"name":"Hz","can_manage":0,"read_only":0},{"id":10,"type_id":24,"name":"°C","can_manage":0,"read_only":0},{"id":11,"type_id":24,"name":"°К","can_manage":0,"read_only":0},{"id":12,"type_id":24,"name":"°F","can_manage":0,"read_only":0},{"id":13,"type_id":25,"name":"Mass Percent","can_manage":0,"read_only":0},{"id":14,"type_id":25,"name":"% volume","can_manage":0,"read_only":0},{"id":15,"type_id":25,"name":"Mass / % volume","can_manage":0,"read_only":0},{"id":16,"type_id":25,"name":"Parts per Million (PPM)","can_manage":0,"read_only":0},{"id":17,"type_id":25,"name":"Parts per Billion (PPB)","can_manage":0,"read_only":0},{"id":18,"type_id":25,"name":"Parts per Trillion (PPT)","can_manage":0,"read_only":0},{"id":19,"type_id":25,"name":"Mole Fraction","can_manage":0,"read_only":0},{"id":20,"type_id":25,"name":"Mole Percent","can_manage":0,"read_only":0},{"id":21,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":1},{"id":22,"type_id":25,"name":"Molarity (M)","can_manage":0,"read_only":0},{"id":23,"type_id":25,"name":"Genome copies per ml","can_manage":0,"read_only":0},{"id":24,"type_id":3,"name":"μV","can_manage":0,"read_only":0},{"id":25,"type_id":3,"name":"ms","can_manage":0,"read_only":0},{"id":26,"type_id":3,"name":"pg","can_manage":0,"read_only":0},{"id":27,"type_id":25,"name":"Molarity dilutions","can_manage":0,"read_only":0},{"id":28,"type_id":25,"name":"millimolar (mM)","can_manage":0,"read_only":0},{"id":29,"type_id":25,"name":"micromolar (µM)","can_manage":0,"read_only":0},{"id":30,"type_id":25,"name":"nanomolar (nM)","can_manage":0,"read_only":0},{"id":31,"type_id":25,"name":"picomolar (pM)","can_manage":0,"read_only":0},{"id":32,"type_id":24,"name":"Room temperature","can_manage":0,"read_only":0},{"id":33,"type_id":30,"name":"rpm","can_manage":0,"read_only":0},{"id":34,"type_id":30,"name":"x g","can_manage":0,"read_only":0},{"id":165,"type_id":24,"name":"On ice","can_manage":0,"read_only":0},{"id":200,"type_id":32,"name":"cm","can_manage":0,"read_only":0},{"id":201,"type_id":32,"name":"mm","can_manage":0,"read_only":0},{"id":202,"type_id":32,"name":"µm","can_manage":0,"read_only":0},{"id":203,"type_id":32,"name":"nm","can_manage":0,"read_only":0},{"id":204,"type_id":25,"name":"mg/mL","can_manage":0,"read_only":0},{"id":205,"type_id":25,"name":"µg/µL","can_manage":0,"read_only":0},{"id":206,"type_id":25,"name":"% (v/v)","can_manage":0,"read_only":0},{"id":207,"type_id":3,"name":"V","can_manage":0,"read_only":0},{"id":1324,"type_id":30,"name":"rcf","can_manage":0,"read_only":0},{"id":1359,"type_id":35,"name":"Bar","can_manage":0,"read_only":0},{"id":1360,"type_id":35,"name":"Pa","can_manage":0,"read_only":0}],"uri":"circulating-interleukin-33-levels-in-obesity-and-t-c8qbzvsn","url":"https://www.protocols.io/view/circulating-interleukin-33-levels-in-obesity-and-t-c8qbzvsn","version_class":94691,"version_data":{"id":0,"code":"c8qbzvsn","version_class":94691,"parent_id":null,"parent_uri":null,"is_same_owner":false,"is_parent_public":false,"has_pending_merge_request":false,"has_approved_merge_request":false,"merge_request":null},"version_id":0,"version_uri":"circulating-interleukin-33-levels-in-obesity-and-t-4r3l22k63l1y/v1","versions":[{"id":94691,"title":"Circulating Interleukin-33 Levels in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analyses","title_html":"Circulating Interleukin-33 Levels in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analyses","image":{"source":"https://www.protocols.io/img/default_protocol.png","webp_source":null,"placeholder":"https://www.protocols.io/img/default_protocol.png","webp_placeholder":null},"doi":"dx.doi.org/10.17504/protocols.io.4r3l22k63l1y/v1","uri":"circulating-interleukin-33-levels-in-obesity-and-t-c8qbzvsn","published_on":1707144665,"modified_on":1707144665,"version_class":94691,"version_id":0,"version_code":"c8qbzvsn","version_uri":"circulating-interleukin-33-levels-in-obesity-and-t-4r3l22k63l1y/v1","created_on":1707134083,"categories":null,"type_id":1,"creator":{"name":"Ghalia Missous","affiliation":null,"affiliation_url":null,"username":"ghalia-missous","link":null,"image":{"source":"/img/avatars/002.png","placeholder":"/img/avatars/002.png","webp_source":""}},"stats":{"number_of_comments":0,"last_comment_time":0}}],"warning":""}